Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer [Corrigendum]
Liu Y, Zhang N, Zhang H, et al. Drug Des Devel Ther. 2020;14:3535–3545. The authors have advised due to an error at the time of figure assembly, Figure 7C on page 3543 is incorrect. The correct Figure 7 is shown in Download Article. The authors apologize for this error...
Saved in:
Main Authors: | Liu Y (Author), Zhang N (Author), Zhang H (Author), Wang L (Author), Duan Y (Author), Wang X (Author), Chen T (Author), Liang Y (Author), Li Y (Author), Song X (Author), Li C (Author), Han D (Author), Chen B (Author), Zhao W (Author), Yang Q (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer
by: Liu Y, et al.
Published: (2020) -
Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer
by: Milene Volpato, et al.
Published: (2020) -
Paeoniflorin Sensitizes Breast Cancer Cells to Tamoxifen by Downregulating microRNA-15b via the FOXO1/CCND1/β-Catenin Axis
by: Wang Y, et al.
Published: (2021) -
EDIL3 and VEGF Synergistically Affect Angiogenesis in Endothelial Cells
by: Niu X, et al.
Published: (2023) -
Auraptene Boosts the Efficacy of the Tamoxifen Metabolites Endoxifen and 4-OH-Tamoxifen in a Chemoresistant ER+ Breast Cancer Model
by: Angel Pulido-Capiz, et al.
Published: (2024)